<DOC>
	<DOCNO>NCT01703312</DOCNO>
	<brief_summary>This study evaluate efficacy QGE031 compare omalizumab patient allergic asthma . Each treatment 's effect change concentration inhale allergen require elicit 15 % fall force expiratory volume one second ( FEV1 ) 12 week compare baseline evaluate .</brief_summary>
	<brief_title>A Study Evaluating Efficacy QGE031 Compared Omalizumab Patients With Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Adult patient 18 65 year Positive skin prick test one common airborne allergen Presence airway hyperresponsiveness document provocative concentration methacholine cause 20 % fall FEV1 ( PC20 FEV1 ) less equal 16 mg/mL Presence early asthmatic response demonstrate allergen challenge screen include 15 % fall FEV1 Patients body weight total IgE range specify local country prescribe information omalizumab Pregnant nursing ( lactate ) woman Women childbearing potential unless use highly effective method birth control ( define study protocol ) Smokers Patients poorly control asthma patient asthma exacerbation within past year Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Allergies , asthma , IgE</keyword>
</DOC>